Please login to the form below

Not currently logged in
Email:
Password:

Prevnar

This page shows the latest Prevnar news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s flat sales focus investor attention on M&A

Pfizer’s flat sales focus investor attention on M&A

Once again, cancer drug Ibrance (palbociclib), anticoagulant Eliquis (apixaban) and Xeljanz (tofacitinib) for arthritis and other immunological indications led the charge, backed up by a solid advance for paediatric vaccine Prevnar ... Vaccines for

Latest news

  • Pfizer split still on cards - for tax reasons Pfizer split still on cards - for tax reasons

    cancer therapy Ibrance (palbociclib), arthritis therapy Xeljanz (tofacitinib) and Prevnar pneumonia vaccine family. ... Prevnar grew 16% to top $1.5bn in the quarter, helped by a new indication for use in adults, which added $439m as well as a $40m

  • Soaring sales of Pfizer's Prevnar lead to calls for price cut Soaring sales of Pfizer's Prevnar lead to calls for price cut

    Pfizer has reported a hefty increase in sales of its Prevnar family of pneumonia vaccines, prompting medical charities to call for a price cut. ... Aside from Prevnar, rheumatoid arthritis treatment Xeljanz (tofacitinib) also performed well - rising 66%

  • Pfizer falls as strong dollar and generic erosion bites Pfizer falls as strong dollar and generic erosion bites

    Pfizer's global vaccines sales saw the best growth with sales rising 44% to $1.33bn, predominately on the back of the Prevnar family of inoculations.

  • US panel backs pneumococcal vaccines for seniors US panel backs pneumococcal vaccines for seniors

    The Advisory Committee on Immunization Practices (ACIP) decision places Pfizer's conjugate vaccine Prevnar 13 as the front-line shot, with Merck's polysaccharide-based Pneumovax 23 used to provide ... Moreover, if patients have already received one or

  • Pfizer closes on $1bn label expansion for Prevenar Pfizer closes on $1bn label expansion for Prevenar

    Analysts at JP Morgan have suggested that approval of the new, broader label could lead to Prevenar 13 (which is sold as Prevnar 13 in the US and some other markets) ... Pfizer has submitted a marketing application in the US to add the new indication to

More from news
Approximately 5 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    This was driven largely by higher-than-expected sales of its pneumonia vaccine, Prevnar, which accounted for more than 11% of its total revenues in the third quarter of 2017.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics